Bharat Biotech confirms adverse event in COVAXIN Phase 1 trial

Bharat Biotech has confirmed that its potential COVID-19 vaccine COVAXIN reported an adverse event during the Phase 1 clinical trials in August. "The adverse event was investigated thoroughly and determined as not vaccine-related," Bharat Biotech said in a statement. As per reports, the adverse event occurred in a 35-year-old participant with no co-morbidities who was hospitalised.